The efficacy of pramipixole as an adjuvant treatment with citalopram for treating major depressive disorder

The efficacy of pramipixole as an adjuvant treatment with citalopram for treating major depressive disorder, a randomized placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201312263930N30

Enrollment

Registered

2014-11-27

Start date

2013-10-07

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder. Depressive episode

Interventions

Intervention 1: Citalopram (20mg/day) plus pramipexole (0.180mg/day). Intervention 2: Citalopram (20mg/day) plus placebo.

Treatment - Drugs

Placebo

Citalopram (20mg/day) plus pramipexole (0.180mg/day)

Citalopram (20mg/day) plus placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged 18 to 65 years old, major depressive disorder using DSM-IV diagnostic criteria. Exclusion criteria: serious uncontrolled medical conditions, bipolar mood disorder.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: baseline, week 2, week 4, and week 6. Method of measurement: Hamilton Derepssion Rating Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Ghanizadeh

Shiraz University of Medical sciences

ghanizad@sina.tums.ac.ir+98 70 3627 3070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026